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Role of PPAR-δ in the development of zymosan-
induced multiple organ failure: an experiment
mice study
Maria Galuppo1†, Rosanna Di Paola2†, Emanuela Mazzon2, Tiziana Genovese1,2, Concetta Crisafulli1, Irene Paterniti1,
Elisabetta Cuzzocrea2, Placido Bramanti2, Amar Kapoor3,4, Christoph Thiemermann3,4, Salvatore Cuzzocrea1,2*
Abstract
Background: Peroxisome proliferator-activated receptor (PPAR)-beta/delta is a nuclear receptor transcription factor
that regulates gene expression in many important biological processes. It is expressed ubiquitously, especially
white adipose tissue, heart, muscle, intestine, placenta and macrophages but many of its functions are unknown.
Saturated and polyunsaturated fatty acids activate PPAR-beta/delta, but physiological ligands have not yet been
identified. In the present study, we investigated the anti-inflammatory effects of PPAR-beta/delta activation,
through the use of GW0742 (0,3 mg/kg 10% Dimethyl sulfoxide (DMSO) i.p), a synthetic high affinity ligand, on the
development of zymosan-induced multiple organ failure (MOF).
Methods: Multiple organ failure (MOF) was induced in mice by administration of zymosan (given at 500 mg/kg, i.p.
as a suspension in saline). The control groups were treated with vehicle (0.25 ml/mouse saline), while the
pharmacological treatment was the administration of GW0742 (0,3 mg/kg 10% DMSO i.p. 1 h and 6 h after
zymosan administration). MOF and systemic inflammation in mice was assessed 18 hours after administration of
zymosan.
Results: Treatment with GW0742 caused a significant reduction of the peritoneal exudate formation and of the
neutrophil infiltration caused by zymosan resulting in a reduction in myeloperoxidase activity. The PPAR-beta/delta
agonist, GW0742, at the dose of 0,3 mg/kg in 10% DMSO, also attenuated the multiple organ dysfunction
syndrome caused by zymosan. In pancreas, lung and gut, immunohistochemical analysis of some end points of the
inflammatory response, such as inducible nitric oxide synthase (iNOS), nitrotyrosine, poly (ADP-ribose) (PAR), TNF-
and IL-1as well as FasL, Bax, Bcl-2 and apoptosis, revealed positive staining in sections of tissue obtained from
zymosan-injected mice. On the contrary, these parameters were markedly reduced in samples obtained from mice
treated with GW0742
Conclusions: In this study, we have shown that GW0742 attenuates the degree of zymosan-induced non-septic
shock in mice.
Background
Multiple organ dysfunction syndrome (MODS), pre-
viously known as multiple organ failure (MOF), is
altered organ function in an acutely ill patient requiring
medical intervention to achieve homeostasis. Patients
suffering from multiple organ dysfunction syndrome
comprise a heterogeneous population, which compli-
cates research in its pathogenesis [1].
The condition usually results from infection, injury
(accident, surgery), hypoperfusion and hypermetabolism.
The primary cause triggers an uncontrolled local and
systemic inflammatory response initiated by tissue
damage. At present there is no agent that can reverse
the established organ failure. Intraperitoneal injection of
zymosan, in mice or rats leads, in the course of 1 to 2
weeks, to increasing organ damage and dysfunction [1].
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The aim of this study is to show the therapeutic effect
of GW0742, a PPAR b/δ treatment in mice zymosan-
induced multiple organ failure.
Introduction
Peroxisome proliferator-activated receptors (PPARs) are
nuclear hormone receptors, i.e. ligand-dependent intra-
cellular proteins that stimulate transcription of specific
genes by binding to specific DNA sequences, following
activation by an appropriate ligand. When activated, the
transcription factors exert several functions in develop-
ment and metabolism [2]. There are three PPAR sub-
types encoded by separate genes, showing distinct but
overlapping tissue distribution, and commonly desig-
nated as PPAR-a (NR1C1), PPAR-g (NR1C3) and
PPAR-b/δ (NUC1, NR1C2), or merely -δ [2,3]. In parti-
cular, PPAR-b/δ is an ubiquitous receptor, especially
expressed in white adipose tissue, heart, muscle, intes-
tine, placenta and macrophages [4]. It is activated by
unsaturated or saturated long-chain fatty acids [5], pros-
tacyclin, retinoic acid, and some eicosanoids [6]. Several
animal studies reveal that PPAR-b/δ plays an important
role in the metabolic adaptation of many tissues to
environmental changes [2]. It appears to be implicated
in the regulation of fatty acid metabolism of skeletal
muscle and adipose tissue by controlling the expression
of a gene involved in fatty acid uptake, b-oxidation and
energy uncoupling [7-9].
In this study we wished to investigate the potential
therapeutic role of PPAR-b/δ activation during an
inflammatory process such as, multiple organ dysfunc-
tion syndrome (MODS, also known as multiple organ
failure (MOF) or multiple organ system failure [10])
caused by zymosan. Multiple organ dysfunction syn-
drome is a cumulative sequence of progressive dete-
rioration in function occurring in several organ
systems, frequently seen after septic shock, multiple
trauma, severe burns, or pancreatitis [11-13]. Zymosan
is a non-bacterial, non-endotoxic agent derived from
the cell wall of the yeast Saccharomyces cerevisiae.
When injected into animals, it induces inflammation
by inducing a wide range of inflammatory mediators
[14-20]. It produces acute peritonitis and multiple
organ failure characterized by functional and structural
changes in liver, intestine, lung, and kidneys
[16,18,21,22].
It is known that zymosan administration, in mice,
within 18 h causes both signs of peritonitis and organ
injury [23,24]. The onset of the inflammatory response
caused by zymosan in the peritoneal cavity was asso-
ciated with systemic hypotension, high peritoneal and
plasma levels of NO, maximal cellular infiltration, exu-
date formation, cyclooxygenase activity and pro-inflam-
matory cytokines production [23,24]. In this model, we
have studied the effect of GW0742, a synthetic high affi-
nity ligand for PPAR-b/δ, after zymosan-induced injury.
Materials and methods
Animals
Male CD mice (20-22 g; Charles River; Milan; Italy)
were housed in a controlled environment and provided
with standard rodent chow and water. The study was
approved by the University of Messina Review Board
for the care of animals. Animal care was in compliance
with Italian regulations on protection of animals used
for experimental and other scientific purposes
(D.M.116192) as well as with the EEC regulations (O.J.
of E.C. L 358/1 12/18/1986)
Zymosan-induced shock
Mice were randomly allocated into the following groups:
(1) Zymosan + vehicle group. Mice were treated intra-
peritoneally (i.p.) with zymosan (500 mg/kg, suspended
in saline solution, i.p.) and with the vehicle for GW0742
(10% dimethylsulfoxide (DMSO) (v/v) i.p), 1 and 6 h
after zymosan administration, n = 10; (2) Zymosan +
GW0742 group. Identical to the Zymosan + vehicle
group but were administered GW0742 (0,3 mg/kg 10%
DMSO i.p) at 1 and 6 hour after zymosan instead of
vehicle, n = 10; (3) Sham + vehicle group. Identical to
the Zymosan + vehicle group, except for the administra-
tion of saline instead of zymosan, n = 10; (4) Sham +
GW0742 group. Identical to Sham + vehicle group,
except for the administration of GW0742 (0,3 mg/kg in
10% DMSO i.p) 1 and 6 hour after saline administration,
n = 10. Eighteen hours after administration of zymosan,
animals were assessed for shock as described below. In
another set of experiments, animals (n = 30 for each
group) were randomly divided as described above
and monitored for loss of body weight and mortality for
7 days after zymosan or saline administration.
Clinical scoring of systemic toxicity
Clinical severity of systemic toxicity in the mice was
scored during the experimental period, (7 days) after
zymosan or saline injection, on a subjective scale ran-
ging from 0 to 3; 0 = absence, 1 = mild, 2 = moderate,
3 = serious. The scale was used for each of the toxic
signs (conjunctivitis, ruffled fur, diarrhea and lethargy)
observed in the animals. The final score was produced
upon totaling each evaluation (maximum value 12). All
clinical score measurements were performed by an inde-
pendent investigator, who had no knowledge of the
treatment received by each respective animal.
Assessment of acute peritonitis
Eighteen hours after zymosan or saline injection, all ani-
mals (n = 10 for each group) were killed under ether
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anesthesia in order to evaluate the development of acute
inflammation in the peritoneum. Through an incision in
the linea alba, 5 ml of phosphate buffered saline (PBS,
composition in mM: NaCl 137, KCl 2.7, NaH2PO4 1.4,
Na2HPO4 4.3, pH 7.4) was injected into the abdominal
cavity. Washing buffer was removed with a plastic pip-
ette and was transferred into a 10 ml centrifuge tube.
The amount of exudate was calculated by subtracting
the volume injected (5 ml) from the total volume recov-
ered. Peritoneal exudate was centrifuged at 7000 × g for
10 min at room temperature.
Peritoneal cell exudate collection and differential staining
At 18 h after treatment, the mice were anesthetized with
intramuscular injection of ketamine/xylazine. The mice
were injected with 5 mL of ice-cold RPMI-1640 medium
(Gibco Inc., Grand Island, NY) with 10% heparin (50 U.
I./ml), into the abdominal cavity. The peritoneal cavities
were massaged for 1 min and the lavage fluid was col-
lected. Peritoneal exudates cell (PEC) counts were car-
ried out in a hemocytometer by mixing 100 μL of
peritoneal cell exudate and 100 μL of eosin. The PEC
was spin in a cytocentrifuge at 50 × g for 5 min onto a
slide for the differential count. The slides were carefully
removed and allowed to air dry briefly. PEC cytospins
were stained with Wright-Giemsa stain. PEC cytospins
were also stained with neutrophil/mast cell-specific
chloroacetate esterase staining and macrophage/mono-
cyte-specific alpha naphthyl butyrate esterase stains for
the differential count.
Measurement of nitrite/nitrate concentrations
Nitrite/nitrate (NO2/NO3) production, an indicator of
NO synthesis, was measured in plasma and in the exu-
date samples collected 18 hours after zymosan or saline
administration, as previously described [23,25]. Nitrate
concentrations were calculated by comparison with
OD550 of standard solutions of sodium nitrate prepared
in saline solution.
Immunohistochemical localization of nitrotyrosine, PARP,
ICAM-1, P-Selectin, Bax, Bcl-2, TNF-a, IL-1b and FasL
Tyrosine nitration and PARP activation were detected,
as previously described [26], in lung, liver and intestine
sections using immunohistochemistry. At 18 hours after
zymosan or saline injection, tissues were fixed in 10%
(w/v) PBS-buffered formalin and 8 μm sections were
prepared from paraffin embedded tissues. After deparaf-
finization, endogenous peroxidase was quenched with
0.3% (v/v) hydrogen peroxide in 60% (v/v) methanol for
30 min. The sections were permeabilized with 0.1% (v/v)
Triton X-100 in PBS for 20 min. Non-specific
adsorption was minimized by incubating the section in
2% (v/v) normal goat serum in PBS for 20 min. Endo-
genous biotin or avidin binding sites were blocked by
sequential incubation for 15 min with avidin and biotin
(Vector Laboratories, Burlingame, CA). The sections
were then incubated overnight with 1:1000 dilution of
primary anti-nitrotyrosine antibody (Millipore, 1:500 in
PBS, v/v), anti-poly(ADP)-ribose (PAR) antibody (Santa
Cruz Biotechnology, 1:500 in PBS, v/v), purified hamster
anti-mouse ICAM-1 (CD54) (1:500 in PBS, w/v) (DBA,
Milan, Italy), purified goat polyclonal antibody directed
towards P-selectin which reacts with mice, anti-Bax rab-
bit polyclonal antibody (1:500 in PBS, v/v), anti-Bcl-2
polyclonal antibody rat (1:500 in PBS, v/v), anti-TNF-a
antibody (Santa Cruz Biotechnology, 1:500 in PBS, v/v),
anti-IL-1b antibody (Santa Cruz Biotechnology, 1:500 in
PBS, v/v), or anti-Fas Ligand antibody (Abcam,1:500 in
PBS, v/v). Controls included buffer alone or non-specific
purified rabbit IgG. Specific labeling was detected with a
biotin-conjugated specific secondary anti-IgG and avi-
din-biotin peroxidase complex (Vector Laboratories,
Burlingame, CA). To verify the binding specificity for
nitrotyrosine, PARP, ICAM-1, P-Selectin, Bax, Bcl-2,
TNF-a and IL-1b and FasL, some sections were also
incubated with primary antibody only (no secondary
antibody) or with secondary antibody only (no primary
antibody). In these situations, no positive staining was
found in the sections indicating that the immunoreac-
tions were positive in all the experiments carried out. In
order to confirm that the immunoreactions for the
nitrotyrosine were specific some sections were also incu-
bated with the primary antibody (anti-nitrotyrosine) in
the presence of excess nitrotyrosine (10 mM) to verify
the binding specificity.
Terminal deoxynucleotidyl transferase-mediated
dUTP-biotin end labeling assay
Terminal deoxynucleotidyl transferase-mediated dUTP-
biotin end labeling assay (TUNEL) was conducted by
using a TUNEL detection kit according to the manufac-
turer’s instruction (Apotag horseradish peroxidase kit;
DBA, Milan, Italy). Briefly, sections were incubated with
15 2 g/Ml proteinase K for 15 min at room temperature
and then washed with PBS. Endogenous peroxidase was
inactivated by 3% H2O2 for 5 min at room temperature
and then washed with PBS. Sections were immersed in
terminal deoxynucleotidyl transferase (TdT) buffer con-
taining deoxynucleotidyl transferase and biotinylated
deoxyuridine 5-triphosphate in TdT buffer, incubated in
a humid atmosphere at 37-C for 90 min, and then
washed with PBS. The sections were incubated at room
temperature for 30 min with anti-fluorescein isothiocya-
nate horseradish peroxidase-conjugated antibody, and
the signals were visualized with diaminobenzidine.
Galuppo et al. Journal of Inflammation 2010, 7:12
http://www.journal-inflammation.com/content/7/1/12
Page 3 of 28
Subcellular fractionation, nuclear protein extraction and
Western blot analysis for iNOS, IB-a, NF-B p65,
Bax and Bcl-2
Tissues were homogenized in cold lysis buffer A (HEPES
10 mM pH = 7.9; KCl 10 mM;EDTA 0.1 mM; EGTA 0.1
mM; DTT 1 mM; PMSF 0.5 mM; Trypsin inhibitor
15 μg/ml; PepstatinA 3 μg/ml; Leupeptin 2 μg/ml; Benza-
midina 40 μM). Homogenates were centrifuged at
12000 g for 3 min at 4°C, and the supernatant (cytosol +
membrane extract) was collected to evaluate contents of
iNOS, IkB-a, Bax, Bcl-2 and b-actin. The pellet was
resuspended in buffer C (HEPES 20 mM; MgCl2 1.5 mM;
NaCl 0.4 mM; EDTA 1 mM; EGTA 1 mM; DTT 1 mM;
PMSF 0.5 μg/ml; Leupeptin 2 μg/ml; Benzamidina
40 μM; NONIDET P40 1%; Glicerolo 20%) and centri-
fuged at 12000 g for 12 min at 4°C, and the supernatant
(nuclear extract) was collected to evaluate the content of
NF-kB p65 and LaminB1. Protein concentration in the
homogenate was determined by Bio-Rad Protein Assay
(BioRad, Richmond CA) and 50 μg of cytosol and nuclear
extract from each sample was analysed. Proteins were
separated by 12% SDS-polyacrylamide gel electrophoresis
and transferred on a PVDF membrane (Hybond-P Nitro-
cellulose, Amsherman Biosciences, UK). The membrane
was blocked with 0.1% TBS-Tween containing 5% non
fat milk for 1 h at room temperature. After the blocking,
the membranes were incubated with the relative primary
antibody overnight at 4°C; anti-iNOS TYPE II diluted
1:1000 (Transduction Laboratories), anti-IkB-a diluted
1:1000, anti-Bax diluted 1:500, anti-Bcl2 diluted 1:1000,
anti-NFkB p65 diluted 1:250, anti-b-actin 1:5000 (Santa
Cruz Biotechnology, CA) and anti-Laminin B1. After the
incubation, the membranes were washed three times for
ten minutes with 0.1% TBS Tween and were then incu-
bated for one hour with peroxidase-conjugated anti-
mouse or anti-rabbit secondary antibodies (Jackson
ImmunoResearch Laboratories, USA) diluted 1:2000, the
membranes were then washed three times for ten min-
utes and protein bands were detected with SuperSignal
West Pico Chemioluminescent (PIERCE). Densitometric
analysis was performed with a quantitative imaging sys-
tem (ImageJ).
Cytokines Production
The levels of TNF and IL-1b were evaluated in the
plasma at 18 hours after zymosan or saline administra-
tion. The assay was conducted using a colorimetric
commercial kit (Calbiochem-Novabiochem, La Jolla,
CA). The ELISA has a lower detection limit of 10 pg/ml.
Measurement of myeloperoxidase activity
Myeloperoxidase (MPO) activity, which was used as an
indicator of PMN infiltration into the lung and intestinal
tissues, was measured as previously described [27].
Quantification of organ function and injury
Blood samples were taken at 18 h after zymosan or sal-
ine injection and centrifuged (1610 × g for 3 min at
room temperature) to separate plasma. Levels of amy-
lase, lipase, creatinine, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), bilirubine and alkaline
phosphatase were measured by a veterinary clinical
laboratory using standard laboratory techniques. For the
evaluation of acid base balance and blood gas analysis
(indicator of lung injury) arterial blood levels of pH,
PaO2 and PaCO2 and bicarbonate ion (HCO3
-) were
determined by pH/Blood gases Analyser as previously
described [28].
Light microscopy
Lung, liver and small intestine samples were taken
18 hours after zymosan or saline injection. The tissue
slices were fixed in Dietric solution [14.25% (v/v) ethanol,
1.85% (w/v) formaldehyde, 1% (v/v) acetic acid] for
1 week at room temperature, dehydrated by graded etha-
nol and embedded in Paraplast (Sherwood Medical, Mah-
wah, New Jersey, USA). Sections (thickness 7 μm) were
deparaffinized with xylene, stained with hematoxylin and
eosin and observed in Dialux 22 Leitz microscope.
Materials
Unless stated otherwise, all reagents and compounds
were obtained from Sigma Chemical Company (Milan,
Italy).
Data analysis
All values in the figures and text are expressed as mean
± standard error of the mean (s.e.m.) of n observations.
For the in vivo studies, n represents the number of ani-
mals studied. In the experiments involving histology or
immunohistochemistry, the figures shown are represen-
tative of at least three experiments (histological or
immunohistochemistry coloration) performed on differ-
ent experimental days on the tissue sections collected
from all animals in each group. The results were ana-
lyzed by one-way ANOVA followed by a Bonferroni’s
post-hoc test for multiple comparisons. A p-value of less
than 0.05 was considered significant. Statistical analysis
for survival data was calculated by Kaplan-Meier survi-
val analysis The Mann-Whitney U test (two-tailed, inde-
pendent) was used to compare medians between the
body weight and the clinical score. For such analyses,
p < 0.05 was considered significant.
Results
Pancreas, lung and gut injury (histological evaluation)
caused by zymosan is reduced in GW0742 treated mice
At 18 h after zymosan administration, histological eva-
luation of pancreas (Figure 1D) lung (Figure 1E) and
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gut (Figure 1F) sections demonstrated several marked
pathological changes. In the pancreas, there was extra-
vasation of neutrophils (Figure 1D). Lung biopsy
revealed inflammatory infiltration by neutrophils,
macrophages and plasma cells (Figure 1E). In the gut,
there was infiltration of inflammatory cells, edema in
the space bounded by the villus, and separation of the
epithelium from the basement membrane (Figure 1F).
Treatment with GW0742 markedly reduced the histo-
logical damage in the pancreatic (Figure 1G), pulmon-
ary (Figure 1H) and intestinal (Figure 1I) tissue. No
histological alteration was observed in the pancreas
(Figure 1A), lung (Figure 1B) or gut (Figure 1C) from
sham-treated mice.
Effect of GW0742-treatment on zymosan-induced body
weight loss and mortality
Administration of zymosan caused severe illness in the
mice, characterized by systemic toxicity and significant
loss of body weight (Figure 2A, 1B). At the end of the
observation period (7 days), 75% of zymosan-treated
mice were dead (Figure 2C). Treatment with GW0742
reduced the development of systemic toxicity (Figure
2A), loss in body weight (Figure 2B) and mortality (Fig-
ure 2C), caused by zymosan. GW0742 treatment did not
cause any significant changes in these parameters in
sham mice (Figure 2A, 2B, 2C).
Effect of GW0742 -treatment on inflammatory response in
the peritoneal cavity
The development of acute peritonitis occurred 18 h
after zymosan administration was indicated by the pro-
duction of turbid exudates (Figure 3A). The total num-
ber of peritoneal exudate cells (PEC) (Figure 3B) was
determined by trypan blue staining following intraperi-
toneal administration of zymosan or saline solution.
This demonstrated a significant increase in the polymor-
phonuclear leukocyte number when compared with
Figure 1 No histological alteration was observed in the pancreas (a), lung (b) or gut (c) from sham-treated mice Pancreas (d) lung (e)
and distal ileum (f) sections from zymosan-administered mice revealed morphological alterations and inflammatory cell infiltration.
Pancreas (g) lung (h) and distal ileum (i) from zymosan-administered mice treated with GW0742 demonstrated reduced morphological
alterations and inflammatory cell infiltration. Figures are representative of at least 3 experiments performed on different experimental days.
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sham mice, which demonstrated no abnormalities in the
peritoneal cavity or fluid.
Zymosan injection in mice was associated with an
increase in PEC counts at 18 h, when compared to the
saline controls (Figure 3B). Since there was a quantita-
tive increase in PECs following zymosan injection, cytos-
pin preparations were performed of the PEC for a
differential estimation of the types of cells present.
Wright-Giemsa stained slides of all controls appeared to
contain mostly mononuclear cells including resident
macrophages and lymphocytes and very few polymor-
phonuclear neutrophils, as previously demonstrated [29].
All cells appeared healthy and intact. At 18 h after
zymosan administration, almost all cells appeared lysed,
and because of excessive phagocytosis by the leukocytes,
the neutrophils could not be differentiated from macro-
phages. Since the cells appeared lysed and the nucleus
could not be differentiated, cell staining for specific
esterases for neutrophil and macrophages were carried
out in order to attempt differentiation between cell
populations in the zymosan treated animals. In agree-
ment with previous observations [29], we confirmed the
presence of 90% mononuclear cells in the peritoneal
cavity along with 10% PMNs in all the sham-treated ani-
mals. In contrast, the zymosan-treated samples could
not be differentiated due to excessive phagocytosis and
lysis of cells. Exudate formation (Figure 3A) and the
degree of PEC count (Figure 3B) were significantly
reduced in mice treated with GW0742.
Effect of GW0742 on IB-a degradation and NF-B p65
activation
To investigate the inflammatory cellular mechanisms by
which treatment with GW0742 may attenuate the devel-
opment of zymosan-induced injury, we evaluated IB-a
degradation and nuclear NF-B p65 translocation by
Western Blot analysis. A basal level of IB-a was
detected in the lung tissues of sham-animals (Figure 4a,
see densitometric analysis Figure 4a1), whereas in zymo-
san-treated mice, IB-a levels were substantially
Figure 2 Effect of GW0742-treatment on toxicity score (A), body weight change (B) and mortality (C). Data are means ± SEM of 10 mice
for each group. *P < 0.01 vs sham, °P < 0.01 vs zymosan + vehicle.
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reduced (Figure 4a, see densitometric analysis Figure
4a1). GW0742 prevented zymosan-induced IB-a degra-
dation, with IB-a levels observed in these animals simi-
lar to those of the sham group (Figure 4a, see
densitometric analysis Figure 4a1). In addition, zymosan
administration caused a significant increase in NF-kB
p65 levels in the nuclear fractions from lung tissues,
compared to the sham-treated mice (Figure 4b, see den-
sitometric analysis Figure 4b1). GW0742 treatment sig-
nificantly reduced the levels of NF-kB p65 in the lung
(Figure 4a, see densitometric analysis Figure 4a1).
Effect of GW0742-treatment on cytokines production
The modulation of GW0742 on the inflammatory pro-
cess through the regulation of cytokine secretion was
assessed by determination of plasmatic levels of the pro-
inflammatory cytokines TNF-a and IL-1b. A substantial
increase in TNF-a and IL-1b formation was observed in
zymosan-treated mice when compared to sham mice
(Figure 5A, 5B, respectively), while a significant inhibi-
tion of TNF-a and IL-1b was observed when animals
with zymosan-induced injury were treated with
GW0742 (Figure 5B, respectively). In addition, tissue
sections of pancreas, lung and gut obtained from ani-
mals 18 h after zymosan administration, demonstrated
positive staining for TNF-a and IL-1-b in pancreas,
(Figure 6A, 7A respectively) lung (Figure 6B, 7B respec-
tively) and gut(Figure 6C, 7C respectively) On the con-
trary the staining for TNF-a and IL-1-b was visibly and
significantly reduced in zymosan mice treated with
GW0742 in pancreas, (Figure 6D, 7D respectively) lung
(Figure 6E, 7E respectively) and gut (Figure 6F, 7F
respectively). In the pancreas, lungs and gut of sham
animals no positive staining was observed for TNF-a
(data not shown) or IL-1-b (data not shown).
Effect of GW0742- treatment on ICAM and P-selectin
expression
At 18 h after zymosan administration, expression of the
adhesion molecules ICAM-1 and P-selectin were evalu-
ated to assess neutrophil infiltration. In zymosan-treated
mice, an increase of immunohistochemical staining for
ICAM-1 and P-selectin was demonstrated in the pan-
creas (Figure 8A, 9A respectively) lung (Figure 8B, 9B
respectively) and gut(Figure 8C, 9C respectively), (see
arrows) while the immunostainings for ICAM-1 and P-
selectin were markedly reduced in pancreas (Figure 8D,
9D respectively) lung (Figure 8E, 9E respectively) and
gut(Figure 8F, 9F respectively) tissues obtained from
mice, that were treated with GW0742. No staining for
either ICAM-1 or P-selectin was found in tissue sections
obtained from sham-treated mice (data not shown).
Effect of GW0742- treatment on inflammatory cell
infiltration
The accumulation of neutrophils in the intestine and
lung is a hallmark of multiple organ failure induced by
zymosan. An indirect assessment of neutrophil infiltra-
tion was carried out by measuring the activity of myelo-
peroxidase (MPO), an enzyme that is contained in (and
specific for) PMN lysosome dysfunction [23,25]. At 18 h
after zymosan administration, MPO activity was signifi-
cantly increased in the lungs (Figure 10A) and gut (Fig-
ure 10B) of zymosan-challenged mice, when compared
with sham-operated mice (Figure 10A, B). MPO activity
was markedly reduced in the lungs (Figure 10A) and gut
Figure 3 Effect of GW0742-treatment on inflammatory response in the peritoneal cavity. The increase in volume exudates (A) and
peritoneal exudates cell leukocyte counts (B) in peritoneal cavity at 18 h after zymosan was reduced by GW0742 treatment. Data are mean ±
standard deviation from n = 10 mice for each group. *P < 0.01 vs sham, °P < 0.01 vs zymosan + vehicle.
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Figure 4 Effect of GW0742-treatment on IkB-a degradation and NF-kB p-65 activation. By Western Blot analysis, a basal level of IkB-a was
detected in the lung tissue from sham-operated animals, whereas in zymosan-induced mice IkB-a levels were substantially reduced (a, see
densitometric analysis a1). Treatment with GW0742 significantly increases the levels of IkB-a, after zymosan injection. Moreover, at 18 h following
zymosan-treatment, the levels of NF-kB p-65 subunit protein in the nuclear fractions of the lung tissue were also significant increased compared
to the sham-operated mice (b, see densitometric analysis b1). The levels of NF-kB p-65 protein were significantly reduced in the nuclear fractions
of the lung tissues from animals that had received GW0742 treatment (b, see densitometric analysis b1). b-actin (a) and Laminin B1 (b) were
used as internal control. The result in a1 and b1 are expressed as mean ± S.E. mean from five blots. P < 0.01 vs sham, °P < 0.01 vs zymosan +
vehicle.
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Figure 5 Effect of GW0742 on plasma tumor necrosis factor alpha (TNF-a) and interleukin-1b (IL-1b) production A substantial increase
in TNF-a (A) and IL-1b (B) production was found in tissues collected from zymosan-treated-mice compared to sham mice. Plasma levels
of TNF-a and IL-1b were significantly attenuated by the treatment with GW0742, 0.3 mg/Kg 10% DMSO i.p. at 1 and 6 hour after zymosan-
injection (A, B, respectively). Data are mean ± standard deviation from n = 10 mice for each group. *P < 0.01 vs sham, °P < 0.01 vs zymosan +
vehicle.
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Figure 6 and immunohistochemical localization of TNF-a in pancreas, lung and gut. 18 hours following zymosan injection, a positive
TNF-a staining was found in pancreas (A), lung (B) and gut (C). There was no detectable immunostaining for TNF-a in pancreas (D), lung (E)
and gut (F) of zymosan-treated mice when mice were treated with GW0742. Figures are representative of at least 3 experiments
performed on different experimental days.
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Figure 7 immunohistochemical localization of IL-1b in pancreas, lung and gut. 18 hours following zymosan injection, a positive IL-1b
staining was found in pancreas (A), lung (B) and gut (C). There was no detectable immunostaining for IL-1b in pancreas (D), lung (E) and gut (F)
of zymosan-treated mice when mice were treated with GW0742. Figures are representative of at least 3 experiments performed on different
experimental days.
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Figure 8 Immunohistochemical localization of ICAM-1 in pancreas, lung and gut. 18 hours following zymosan injection, a positive ICAM-1
staining was found in pancreas (A), lung (B) and gut (C). There was no detectable immunostaining for ICAM-1 in pancreas (D), lung (E) and gut
(F) of zymosan-treated mice when mice were treated with GW0742. Figures are representative of at least 3 experiments performed on different
experimental days.
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Figure 9 Immunohistochemical localization of P-Selectin in pancreas, lung and gut. 18 hours following zymosan injection, a positive P-
Selectin staining was found in pancreas (A), lung (B) and gut (C). There was no detectable immunostaining for P-Selectin in pancreas (D), lung
(E) and gut (F) of zymosan-treated mice when mice were treated with GW0742. Figures are representative of at least 3 experiments performed
on different experimental days.
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Figure 10 Moreover, MPO activity in lung (A) and gut (B) samples of zymosan-treated-mice was significantly increased in comparision
to sham mice (A and B, respectively). Treatment with GW0742 significantly reduced the increase of MPO activity in lung (A) and gut (B). Data
are mean ± standard deviation from n = 10 mice for each group. *P < 0.01 vs sham, °P < 0.01 vs zymosan + vehicle.
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(Figure 10B) of zymosan-challenged mice treated with
GW0742.
Effect of GW0742 treatment on NO formation and iNOS
expression
The analysis of exudates (Figure 11A) and plasma (Fig-
ure 11B) levels validate the biochemical and inflamma-
tory changes observed in the peritoneal cavity of
zymosan-treated mice, showing a significant increase of
nitrite/nitrate (NOx) concentration (Figure 11A, 11B,
respectively) when compared with sham-operated mice.
These values were significantly reduced in mice treated
with GW0742 (Figure 11A, 11B, respectively). We
assessed iNOS expression in samples of pulmonary tis-
sue by Western Blot analysis (Figure 11Ca, see densito-
metric analysis a1). A significant increase in iNOS
expression has been demonstrated in samples of lung
obtained from zymosan-injected mice, when compared
with sham-operated mice (Figure 11Ca, see densito-
metric analysis a1). In contrast, a significant decrease in
iNOS expression was clearly observed in the zymosan-
challenged mice treated with GW0742 (Figure 11Ca, see
densitometric analysis a1).
Effect of GW0742 -treatment on nitrosative stress and
PARP activation
To determine the localization of “peroxynitrite forma-
tion” and/or other nitrogen derivatives produced during
multiple organ failure, zymosan-induced nitrotyrosine, a
specific marker of nitrosative stress, was measured by
immunohistochemical analysis in sections of pancreas,
lung and gut tissues, using a specific anti-nitrotyrosine
antibody. The samples obtained from sham-operated
mice did not stain for nitrotyrosine (data not shown),
while sections from zymosan-induced mice exhibited
positive staining for nitrotyrosine in pancreas (Figure
12A), lung (Figure 12B) and gut (Figure 12C) tissues
(see arrows). A marked reduction in nitrotyrosine stain-
ing was found in the pancreas (Figure 12D), lung (Figure
12E) and gut (Figure 12F) of the zymosan-challenged
mice treated with GW0742.
Sections of pancreas, lung and gut were taken at 18 h
after zymosan administration in order to determine the
activation of the nuclear enzyme, poly (ADP-ribose)
polymerase (PARP), that has been implicated in the
pathogenesis of multiple organ failure. Thus, we used an
immunohistochemical approach to assess the presence
of PAR, an indicator of PARP activation in vivo. There
was positive staining for PAR localized in sections of
pancreas (Figure 13A), lung (Figure 13B) and gut (Figure
13C) obtained from zymosan-challenged mice. Treat-
ment with GW0742 reduced the degree of positive
staining for PAR in the pancreas (Figure 13D), lung
(Figure 13E) and gut (Figure 13F). No positive staining
for PAR was identified in tissues from Sham-operated
mice (data not shown).
Effect of GW 0742 -treatment on Fas-ligand expression
and apoptosis
Immunohistological staining for the Fas Ligand in the
pancreas (Figure 14A), lung (Figure 14B) and gut (Figure
14C) were determined 18 h after zymosan-induced
injury. Tissue sections from the sham-operated mice did
not stain for the Fas Ligand (data not shown), whereas
sections obtained from the zymosan-challenged mice
exhibited positive staining for the Fas Ligand, in the
pancreas (Figures 14A), lung (Figure 14B) and gut (Fig-
ure 14C). Treatment with GW0742 reduced the degree
of positive staining for the Fas Ligand in the pancreas
(Figures 14D), lung (Figure 14E) and gut (Figure 14F).
To test whether tissue damage was associated with cell
death by apoptosis, we assessed TUNEL-like staining in
pancreas (Figure 15A) and pulmonary tissue (Figure
15B). Almost no apoptotic cells were detectable in sec-
tions of pancreatic and pulmonary tissue in sham-oper-
ated mice (data not shown). At 18 h after zymosan-
induced injury, sections of pancreas (Figure 15A) and
lung (Figure 15B) demonstrated a marked appearance of
dark brown apoptotic cells and intercellular apoptotic
fragments. In contrast, pancreatic (Figure 15C) and pul-
monary (Figure 15D) tissue obtained from zymosan-
administered mice treated with GW0742, demonstrated
a small number of apoptotic cells or fragments.
Western blot analysis and immunohistochemistry for Bax
and Bcl-2
The presence of Bax and Bcl-2 in lung homogenates was
investigated by Western blot 18 hours after zymosan
administration. A basal level of Bax was detected in
lung tissues obtained from sham-treated animals (Figure
16A, see densitometric analysis Figure 16A1). Bax levels
were substantially increased in the lung tissues from
zymosan-administered mice (Figure 16A, see densito-
metric analysis Figure 16A1). In contrast, GW0742
treatment prevented the zymosan-induced Bax expres-
sion (Figure 16A, see densitometric analysis Figure
16A1). A basal level of Bcl-2 was detected in lung tis-
sues obtained from sham-treated animals (Figure 16B,
see densitometric analysis Figure 16B1). Bcl-2 levels
were substantially reduced in the lung tissues from
zymosan-administered mice (Figure 16B, see densito-
metric analysis Figure 16B1). In contrast, GW0742 treat-
ment significantly attenuated the zymosan-induced
reduction of Bcl-2 expression (Figure 16B, see densito-
metric analysis Figure 16B1).
To determine the immunohistological staining for Bax
(Figure 17) and Bcl-2 (Figure 18), samples of pancreas
(Figure 17A, 18A respectively) lung (Figure 17B, 18B,
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respectively) and gut (Figure 17C, 18C respectively) were
also collected 18 hours after zymosan administration.
Tissues taken from sham-treated mice did not stain for
Bax (data not shown), whereas pancreatic (Figure 17A),
pulmonary (Figure 17B) and intestinal (Figure 17C) sec-
tions obtained from zymosan-treated mice exhibited
positive staining for Bax. GW0742 treatment reduced
the degree of positive staining for Bax in the pancreas
(Figure 17D), lung (Figure 17E) and gut (Figure 17F) of
mice subjected to zymosan-induced injury.
In addition, lung sections from sham-treated mice
demonstrated positive staining for Bcl-2 (data not
shown), whereas in zymosan-administered mice, Bcl-2
staining was significantly reduced (Figure 18). GW0742
treatment significantly attenuated the loss of positive
staining for Bcl-2 in pancreatic (Figure 18D), pulmonary
(Figure 18E) and intestinal (Figure 18F) samples of mice
subjected to zymosan-induced injury.
Zymosan-induced multiple organ dysfunction syndrome
is reduced by GW0742
Effects on lung injury
When compared to sham-operated mice, zymosan-
administered mice demonstrated significant alterations
in the PaO2 (Figure 19A), PCO2 (Figure 19B), HCO3
-
(Figure 19C) and pH arterial blood levels (Figure 19D),
suggesting the development of lung dysfunction. In con-
trast, treatment with GW0742 significantly reduced the
Figure 11 Effect of GW0742 on peritoneal exudates (A) and plasma nitrate/nitrite levels (B). Nitrate/nitrite levels were significantly
increased both in peritoneal exudate and in plasma of zymosan-treated mice in comparison to vehicle group (sham group). GW0742 reduced
the zymosan-induced increase of nitrate/nitrite levels in peritoneal exudate (A) and in plasma (B). In addition, by Western Blot analysis the iNOS
expression was evaluated in the lung. At 18 h after zymosan administration a significant increase in the iNOS expression was observed in the
ileum (Ca, see densitometric analysis a1) compared to the sham-treated mice. GW0742 treatment significantly reduced the iNOS expression (Ca,
see densitometric analysis a1). The intensity of bands was measured using a phosphoimager in all the experimental groups. b-actin was used as
internal control. A representative blot of lysates obtained from each group is shown, and densitometric analysis of all animals is reported (n = 5
mice from each group). Data are mean ± standard deviation from n = 10 mice for each group. *P < 0.01 vs sham, °P < 0.01 vs zymosan +
vehicle.
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Figure 12 Immunohistochemical localization of nitrotyrosine in pancreas, lung and gut. 18 h following zymosan injection, a positive
nitrotyrosine staining was found in the pancreas (A), lung (B) and gut (C). There was no detectable immunostaining for nitrotyrosine in the
pancreas (D), lung (E) and gut (F) of zymosan-administered mice when mice were treated with GW0742. Figure is representative of at least 3
experiments performed on different experimental days.
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Figure 13 Immunohistochemical localization of PAR in pancreas, lung and gut. 18 h following zymosan injection, a positive PAR staining
was found in the pancreas (A), lung (B) and gut (C). There was no detectable immunostaining for PAR in the pancreas (D), lung (E) and gut (F)
of zymosan-administered mice when mice were treated with GW0742. Figure is representative of at least 3 experiments performed on different
experimental days.
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Figure 14 Effect of GW0742 on Fas-ligand expression. 18 h following zymosan injection, positive FasL staining was found in pancreas (A),
lung (B) and gut (C). There was no detectable immunostaining for FasL in pancreas (D), lung (E) and gut (F) of zymosan-administered mice
when mice were treated with GW0742. Figures are representative of at least 3 experiments performed on different experimental days.
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lung injury caused by zymosan (Figure 19A, 19B, 19C,
19D).
Hepatocellular injury
When compared to sham-operated mice, zymosan-
administered mice demonstrated significantly high
plasma concentrations of AST (Figure 20A), ALT (Fig-
ure 20B), bilirubin (Figure 20C) and alkaline phospha-
tase (Figure 20D), suggesting the presence of a
consistent hepatocellular injury. In contrast, treatment
with GW0742 significantly reduced the liver injury
caused by zymosan (Figure 20A, 20B, 20C, 20D).
Pancreatic injury
When compared to sham-operated mice, zymosan-
administered mice demonstrated significantly high
plasma concentrations of lipase (Figure 21A) and amy-
lase (Figure 21B), suggesting the development of pan-
creatic injury. In contrast, treatment with GW0742
significantly reduced the pancreatic injury caused by
zymosan (Figure 21A, 21B).
Renal dysfunction
When compared to sham-operated mice, zymosan-
administered mice demonstrated significantly high
plasma concentrations of creatinine (Figure 21C), sug-
gesting the development of renal dysfunction. In con-
trast, treatment with GW0742 significantly reduced the
renal dysfunction caused by zymosan (Figure 21C).
Discussion
Little is known about the peroxisome proliferator-acti-
vated receptor (PPAR)-b/δ compared to the other mem-
bers of the steroid hormone nuclear receptor family,
PPAR-a and PPAR-g [30]. Recently, preclinical in vivo
studies, using high-affinity PPAR-b/δ agonists, have
demonstrated efficacy in models of diabetes as well as
obesity b-oxidation, suggesting that modulation of the
beta/delta isoform may have a role in treating these dis-
eases as well as the metabolic syndrome [30]. Though
the mechanism by which PPAR-b/δ acts remains largely
Figure 15 Effect of GW0742 on TUNEL-like staining. At 18 h after zymosan administration, TUNEL-like staining showed a marked appearance
of dark brown apoptotic cells and intercellular apoptotic fragments in pancreatic (A) pulmonary (B) tissue. On the contrary, the number of dark
brown cells was significantly reduced in pancreas (C) and lung (D) by the treatment with GW0742. Figures are representative of at least 3
experiments performed on different experimental days.
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unknown and not yet fully characterized, we wanted to
demonstrate a possible therapeutic involvement of the
PPAR-b/δ isoform in an acute inflammatory disease
such as zymosan-induced multiple organ failure. We
demonstrated a beneficial role of the PPAR-b/δ agonist,
GW0742, as its treatment decreased the development of
acute peritonitis, organ dysfunction and injury, which
was associated with a severe illness, a survival approxi-
mately of 60% and characterized by systemic toxicity,
and significant loss of body weight.
Our results demonstrate that GW0742, through the
activation of its PPAR-b/δ receptor, not only mediates
anti-inflammatory effects but also attenuates cell death
and apoptosis processes, ameliorating organ dysfunction
and/or improving survival. We clearly demonstrate that
GW0742 significantly reduced exudate formation and
the degree of PEC count. Moreover, during the study of
other inflammatory diseases, it been shown that several
transcription factors, important to the regulation of
acute inflammation, serve as substrates for PPARs
[31,32]. These include the transcription factor NF-B
(Nuclear Factor Kappa-light-chain-enhancer of activated
B cells), a protein complex that is found in almost all
animal cell types and is involved in cellular responses to
stimuli such as stress, cytokines, free radicals, ultraviolet
irradiation, oxidized LDL, and bacterial or viral antigens
[33-37]. NF-B plays a key role in regulating the
immune response to infection. Consistent with this role,
incorrect regulation of NF-B has been linked to cancer,
inflammatory and autoimmune diseases, septic shock,
viral infection, and improper immune development [38].
In concurrence with this, multiple organ dysfunction
syndrome (MODS) causes liberation of NF-B p65 by
its physiological inhibitor, IBa, and hence nuclear
translocation where it activates the inflammatory path-
way. NF-B p65 function is strikingly altered by PPAR
activation. By Western Blot analysis, we report here that
zymosan-induced non-septic shock was associated with
significant IB-a degradation as well as increased
nuclear localization of NF-kB p65 in the lung at 18 h
after zymosan administration. GW0742-treatment signif-
icantly reduced IBa degradation as well as nuclear
translocation of p65. Thus, in this in vivo model system,
GW0742 appeared to inhibit NF-B activation, main-
taining high cytoplasm levels of IkBa.
PPAR-b/δ activation also attenuates the increase of
many cytokines, such as TNF-a and IL-1b, involved in
the inflammatory response. There is evidence that the
pro-inflammatory cytokines, TNF-a and IL-1b help to
propagate the extension of a local or systemic inflamma-
tory process [39,40]. In the present study, zymosan-
induced shock causes a substantial increase in the levels
of both TNF-a and IL-1b in the plasma after 18 h,
while it is clear that GW0742 blocks the mechanisms
Figure 16 Western Blot analysis of Bax and Bcl-2 expression. Representative Western Blot of Bax and Bcl-2 levels was realized in pulmonary
samples at 18 h after zymosan-injection. At 18 h after zymosan administration, a significant increase in the Bax expression was observed in the
lung (A, see densitometric analysis A1) compared to the sham-treated mice, whereas in GW0742-treated mice Bax levels were substantially
reduce (A, see densitometric analysis A1). On the contrary, at 18 h after zymosan administration, a decrease in the Bcl-2 expression was observed
in the lung (B, see densitometric analysis B1) compared to the sham-treated mice, while Bcl-2 expression was more evident in the pulmonary
tissue from zymosan-treated mice that received GW0742 treatment (B, see densitometric analysis B). Data are mean ± standard deviation from
n = 10 mice for each group. *P < 0.01 vs sham, °P < 0.01 vs zymosan + vehicle.
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Figure 17 Immunohistochemical localization of Bax. Moreover, Bax expression was also evaluated by immunohistochemical analysis in
pancreas, lung and gut. 18 hours following zymosan injection, positive Bax staining was found in pancreas (A), lung (B) and gut (C). No positive
staining for Bax was detected in pancreas (D), lung (E) and gut (F) of zymosan-treated mice when mice were treated with GW0742. Figures are
representative of at least experiments performed on different experimental days.
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Figure 18 Immunohistochemical localization of Bcl-2 expression. Moreover, Bcl-2 expression was also evaluated by immunohistochemical
analysis in pancreas, lung and gut. At 18 h after zymosan administration, no positive staining for Bcl-2 was observed in pancreas (A), lung (B)
and gut (C) from zymosan-treated mice. On the contrary, positive staining for Bcl-2 was observed in pancreas (D), lung (E) and gut (F) from mice
treated with GW0742. Figures are representative of at least experiments performed on different experimental days.
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generating an overproduction of TNF-a and IL-1b.
These data are confirmed by immunohistochemical
localization of these cytokines. Indeed, the assessment of
pancreatic, pulmonary and intestinal tissue sections have
revealed a higher presence of TNF-a and IL-1b in sam-
ples obtained from zymosan-injected mice, while
GW0742 treatment exhibited a fall in the immunohisto-
chemical levels. Moreover, the result of high circulating
TNF and IL-1b plasma levels is the expression of
endothelial adhesion molecules, such as ICAM-1 and P-
selectin that play a pivotal role in the rolling and firm
attachment of neutrophils to the endothelium [28], reg-
ulating the process of neutrophil chemoattraction, adhe-
sion, and emigration from the vasculature to the tissues
[41,42]. In this study, we observed that, 18 h after
administration, zymosan induced the expression of P-
selectin in the endothelium of small vessels and upregu-
lated the surface expression of ICAM-1 and P-Selectin
on endothelial cells in the pancreas, lung and gut. In
contrast, there was significantly less expression of P-
selectin and ICAM-1 in the pancreas, lung and gut
obtained from mice treated with GW0742. Accordingly,
we found, by assessment of MPO levels, that neutrophil
infiltration was significantly reduced upon GW0742
treatment in zymosan-induced injured mice.
Moreover, in zymosan-induced shock and inflamma-
tion the role of nitric oxide (NO), a reactive nitrogen
species, has been demonstrated [43] because of the
induction of iNOS, which contributes to the inflamma-
tory process [24]. NO levels assessed in exudates and
plasma, were increased at 18 h after zymosan-injection,
while GW0742 decreased the levels of NO. By Western
Blot analysis, we have detected the anti-inflammatory
action of GW0742 on iNOS expression, which was
reduced when compared with zymosan-only injected
mice.
Nitrotyrosine formation, along with its detection by
immunostaining, was initially proposed as a relatively
specific marker for the detection of the endogenous
formation “footprint” of peroxynitrite [44] and an
increased nitrotyrosine staining is considered as an
indication of increased nitrosative stress [45]. Thus, by
immunohistochemical localization, we have seen an
increase in nitrotyrosine staining in samples of
Figure 19 Effect of GW0742 on lung injury. Zymosan administration resulted in significant fall in the arterial levels of PaO2 (A), PCO2 (B), pH
(C) and HCO3
-(D). Administration of GW0742 prevents the lung dysfunctions. Data are means ± SEM of 10 mice for each group. *P < 0.01 vs
sham, °P < 0.01 vs zymosan + vehicle.
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pancreas, lung and gut obtained from zymosan-
induced injured mice, while an improvement was due
to GW0742 administration.
Therefore, in this experiment, it is not unexpected
that we found that multiple organ failure results also in
the formation of peroxynitrite and it is well known that
the nuclear enzyme poly (ADP-Ribose) synthetase
(PARS) activation can be a consequence of peroxynitrite
production [46,47]. A novel pathway of inflammation
has been proposed in relation to ROS (hydroxyl radical
and peroxynitrite) induced strand breaks in DNA, which
trigger energy-consuming DNA repair mechanisms and
activates PARP, resulting in the depletion of its substrate
NAD+ in vitro and a reduction in the rate of glycolysis.
As NAD+ functions as a cofactor in glycolysis and the
tricarboxylic acid cycle, NAD+ depletion leads to a rapid
fall in intracellular ATP. This process has been termed
‘the PARP Suicide Hypothesis’. Thus, a markedly immu-
nohistochemical staining of PARP was detected in sec-
tions of pancreas, lung and gut from zymosan-treated
mice, while, here, we have observed a decrease of PARP
activity in samples of mice treated with GW0742.
The processes that lead to the activation of inflamma-
tory mediators, such as NF-kB p65 or TNF-a are also
crucially involved and closely associated to apoptotic
processes, that occur in FasL expression induced by
DNA-damaging agents, such as a genotoxic drug and
UV radiation [48]. Fas forms the Death Inducing Signal-
ing Complex (DISC) upon ligand binding, a multi-pro-
tein complex formed by members of the death receptor
family of apoptosis-inducing cellular receptors [49]. In
this study, we have clearly shown the degree of cell
death, assessed by immunohistochemical localization of
FasL and TUNEL staining, which highlights the pre-
sence of apoptotic cell bodies. In either case, we found
that zymosan-injection causes an increase of FasL
expression in tissue sections of pancreas, lung and gut
and TUNEL-positive staining with a marked appearance
of dark brown apoptotic cells and intercellular apoptotic
fragments in pancreas and lung tissues. On the other
Figure 20 Effect of GW0742 on liver injury. Administration of zymosan resulted in significantly increased levels of plasma AST (A), ALT (B),
bilirubin (C) and alkaline phosphatase (D). GW0742 treatment significantly reduced all these parameters in zymosan treated mice. Data are mean
± standard deviation from n = 10 mice for each group. *P < 0.01 vs sham, °P < 0.01 vs zymosan + vehicle.
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hand, the GW0742-mediated activation of PPAR-b/δ
confirms the beneficial role in multiple organ failure,
decreasing the value of previous apoptotic parameters.
Apoptosis manifests itself in two major execution pro-
grams downstream of the death signal: the caspase path-
way and organelle dysfunction, of which mitochondrial
dysfunction is the best characterized [50,51]. As the Bcl-
2 family members reside upstream of irreversible cellular
damage and focus’ much of their efforts at the level of
the mitochondria, it plays a pivotal role in deciding
whether a cell will live or die. The Bcl-2 family of pro-
teins has expanded significantly and includes both pro-
as well as anti-apoptotic molecules. Indeed, the ratio
between these two subsets helps determine, in part, the
susceptibility of cells to a death signal [52].
Thus, the Western Blot analysis on sections of lung
tissue to detect Bax and Bcl-2 expression, supported the
idea that the zymosan-injection causes an increase of
mitochondrial permeability and severe cellular injury,
which leads to a higher expression of Bax than Bcl-2
production, whereas GW0742 administration reduced
the apoptosis-induced cell death.
Also the immunohistochemical localization of Bax on
sections of pancreatic, pulmonary and intestinal tissue
has revealed a loss of physiological balance between
pro- and anti-apoptotic factors with an increase of Bax
and a decrease of Bcl-2 expression in zymosan-adminis-
tered mice and, in contrast, a reduction of Bax levels in
GW0742-treated animals.
To further confirm these data, we found that GW0742
treatment not only prevents lung dysfunction, and
reduces zymosan-induced loss of blood PaO2, PCO2,
HCO3
- and pH levels, but also diminishes other blood
parameters, such as the levels of AST, ALT, bilirubin and
alkaline phosphatase that are altered after the onset of
zymosan-induced MOF. Furthermore, high concentra-
tions of lipase, amylase and creatinine, indicating the
degree of MODS, are all reduced by GW0742, as shown
here on liver, pancreas, kidney and lung, is significantly
attenuated by PPAR-b/δ activation by GW0742, reducing
the pathophysiology of MOF. A histological resolution of
organ damage to administration of GW0742 was high-
lighted in pancreas, lung and gut by haematoxylin-eosin
staining too. Indeed, the degree of histoarchitectural
Figure 21 Effect of GW0742 on pancreatic and renal injury. Administration of zymosan resulted in significantly increased levels of plasma
amylase (A), lipase (B) and creatinine (C). GW0742 treatment significantly decreases all these parameters in zymosan treated mice. Data are
mean ± standard deviation from n = 10 mice for each group. *P < 0.01 vs sham, °P < 0.01 vs zymosan + vehicle.
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modifications in these tissues decreased significantly after
treatment with GW0742.
Conclusion
The multiple organ failure, replicated here through
zymosan-injection, is a disease with severe implications,
involving several mechanisms not yet fully known.
However, our results clearly suggest that the PPAR-b/δ
agonist, GW0742 may be used successfully as a therapeu-
tic agent in the treatment of conditions associated with
inflammation and multiple organ system dysfunction.
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